"Binding" $1 billion offers are said to be on the table as Indian drugmakers Aurobindo and Intas go head-to-head for Teva's generics business in…

If Mylan was hoping that its new EpiPen copay assistance and authorized generic would stave off government probing, then it’s hoping in vain. Another…

While they're waiting for key outcomes data on their PCSK9 cholesterol-fighters, Amgen, Sanofi and Regeneron are rolling out other studies to help bolster…

Activist investor Bill Ackman broke all of his personal investment rules when he bet big on Valeant Pharmaceuticals. And now he’s calling the move “one very…

Mylan’s EpiPen tornado is far from its first storm of controversy. The top brass has caught fire for personal use of company aircraft, an unearned degree,…

After a week scrabbling to calm the EpiPen pricing crisis, Mylan has unveiled its latest tactic. The drugmaker plans to launch an authorized generic priced at…

The Attorney General of New Hampshire is accusing Purdue Pharma of dragging its feet in his investigation into Purdue’s marketing of its highly addictive…

The FDA has given its okay to Companion Medical’s InPen delivery system, which the company touts as the first U.S.-approved Bluetooth-enabled insulin pen.…